专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090170097A1 GENE EXPRESSION IN BIOLOGICAL CONDITIONS 审中-公开
标题翻译：基因表达生物条件
公开(公告)号：US20090170097A1
公开(公告)日：2009-07-02
申请号：US12180321
申请日：2008-07-25
申请人： Torben Falck Orntoft , Thomas Thykjaer Andersen , Lars Dyrskjot Andersen , Jens Ledet Jensen
发明人： Torben Falck Orntoft , Thomas Thykjaer Andersen , Lars Dyrskjot Andersen , Jens Ledet Jensen
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to a method of predicting the prognosis of a biological condition in animal tissue, wherein the expression of genes is examined and correlated to standards. The invention further relates to the treatment of the biological condition and an assay for predicting the prognosis. In particular, the invention concerns gene expression in epithelial tissue, such as urinary bladder under both normal and abnormal conditions.
摘要翻译：本发明涉及预测动物组织中生物学条件的预后的方法，其中检查基因的表达并与标准相关。本发明还涉及生物学条件的治疗和用于预测预后的测定法。特别地，本发明涉及在正常和异常条件下的上皮组织，例如膀胱中的基因表达。

2. 发明授权

US09499864B2 Expression of FABP4 and other genes associated with bladder cancer progression 有权
标题翻译： FABP4和膀胱癌进展相关基因的表达
公开(公告)号：US09499864B2
公开(公告)日：2016-11-22
申请号：US13316821
申请日：2011-12-12
申请人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6876 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.
摘要翻译：公开的是通过确定FABP4和MBNL2或其他标志物的基因表达水平来预测膀胱癌进展的风险的方法，包括膀胱癌的死亡，其中增加的水平与受试者膀胱癌的进展不足相关，并且降低的水平与进展或来自膀胱癌的死亡和/或确定COL4A1，UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和/或CDC25B或其他增加水平与受试者的膀胱癌或死亡进展相关的其他标志物的基因表达水平，并且降低的水平与膀胱癌的进展不良相关。

3. 发明申请

US20120077703A1 Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression 审中-公开
公开(公告)号：US20120077703A1
公开(公告)日：2012-03-29
申请号：US13323554
申请日：2011-12-12
申请人： Lars Dyrskjot Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjot Andersen , Torben Falck Orntoft
IPC分类号： C40B30/04
CPC分类号： C12Q1/6876 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.

4. 发明申请

US20130183345A1 Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers 审中-公开
标题翻译：检测某些进展标记的表达水平后膀胱癌的治疗
公开(公告)号：US20130183345A1
公开(公告)日：2013-07-18
申请号：US13791370
申请日：2013-03-08
申请人： Lars Dyrskjøt Andersen , Torben Falck Orntoft , Joseph A. Sorge , Alexey Novoradovsky
发明人： Lars Dyrskjøt Andersen , Torben Falck Orntoft , Joseph A. Sorge , Alexey Novoradovsky
IPC分类号： A61K35/74
CPC分类号： A61K35/74 , C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels.
摘要翻译：公开了确定膀胱癌预后和治疗的保护性或有害标志物的表达水平; 特别是确定保护性标记（COL4A3BP，MBNL2，FABP4，NEK1和SKAP2）和有害标记（COL4A1，UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和CDC25B）的表达水平，并考虑到增加或基于标记物表达水平降低进展的风险。

5. 发明申请

US20120082994A1 Expression Levels of COL4A1 and other Markers Correlating with Progression or Non-Progression of Bladder Cancer 审中-公开
标题翻译： COL4A1和其他与膀胱癌进展或非进展相关的标志物的表达水平
公开(公告)号：US20120082994A1
公开(公告)日：2012-04-05
申请号：US13316765
申请日：2011-12-12
申请人： Lars Dyrskjot Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjot Andersen , Torben Falck Orntoft
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed is determining expression levels protective or harmful markers for bladder cancer prognosis; particularly, determining the expression levels of COL4A3BP alone or in combination with the expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlates with bladder cancer progression or death. Also disclosed is determining the expression levels of COL4A1 alone or in any combination with the expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlates with lack of bladder cancer progression Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.
摘要翻译：公开了确定膀胱癌预后的表达水平保护性或有害标记物; 特别是单独确定COL4A3BP的表达水平或结合MBNL2，FABP4和NEK1或其他标志物的表达水平，其中这些保护性标记物相对于对照的增加的表达水平与膀胱癌进展的缺乏和表达水平的降低相关联伴有膀胱癌进展或死亡。还公开了确定单独的COL4A1或与UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和CDC25B或其他标志物的表达水平的任何组合的表达水平，其中这些有害标志物相对于对照的增加的表达水平与膀胱癌进展或死亡以及降低的表达水平与缺乏膀胱癌进展相关。还公开了保护性和有害标记物的特征，以预测膀胱癌进展或非进展的可能性。

6. 发明申请

US20120077202A1 Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression 有权
标题翻译： FABP4和其他与膀胱癌进展相关基因的表达
公开(公告)号：US20120077202A1
公开(公告)日：2012-03-29
申请号：US13316821
申请日：2011-12-12
申请人： Lars Dyrskjot Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjot Andersen , Torben Falck Orntoft
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6876 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.
摘要翻译：公开的是通过确定FABP4和MBNL2或其他标志物的基因表达水平来预测膀胱癌进展的风险的方法，包括膀胱癌的死亡，其中增加的水平与受试者膀胱癌的进展不足相关，并且降低的水平与进展或来自膀胱癌的死亡和/或确定COL4A1，UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和/或CDC25B或其他增加水平与受试者的膀胱癌或死亡进展相关的其他标志物的基因表达水平，并且降低的水平与膀胱癌的进展不良相关。

7. 发明申请

US20090297506A1 Classification of cancer 审中-公开
标题翻译：癌症分类
公开(公告)号：US20090297506A1
公开(公告)日：2009-12-03
申请号：US10584653
申请日：2004-12-23
申请人： Torben Falck Orntoft , Paivi Laiho , Lauri A. Aaltonen , Mogens Kruhoffer , Jens Ledet Jensen
发明人： Torben Falck Orntoft , Paivi Laiho , Lauri A. Aaltonen , Mogens Kruhoffer , Jens Ledet Jensen
IPC分类号： A61K39/395 , A61K39/00 , C12Q1/68 , C12Q1/02 , C12N15/87 , C12N5/06 , A61K31/513 , A61K31/4375 , C07K2/00 , C07H21/04
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/156 , C12Q2600/158
摘要： The invention discloses a method for classification of cancer in an individual having contracted cancer. The method of classification involves the determination of microsatellite status and a prognostic marker by examining gene expression patterns. The invention also relates to various methods of treatment of cancer. Additionally, the present invention concerns a pharmaceutical composition for treatment of cancer and uses of the present invention. The invention also relates to an assay for classification of cancer.
摘要翻译：本发明公开了一种在患有癌症的个体中分类癌症的方法。分类方法包括通过检测基因表达模式来测定微卫星状态和预后标志。本发明还涉及癌症的各种治疗方法。此外，本发明涉及用于治疗癌症的药物组合物和本发明的用途。本发明还涉及癌症分类的检测方法。

8. 发明申请

US20130122504A1 Expression Levels of COL4A3BP and other Markers Correlating with Progression or Non-Progression of Bladder Cancer 审中-公开
标题翻译： COL4A3BP和其他与膀胱癌进展或非进展相关的标志物的表达水平
公开(公告)号：US20130122504A1
公开(公告)日：2013-05-16
申请号：US13316733
申请日：2011-12-12
申请人： Lars Dyrskjot Andersen , Torben Falck Orntoft , Joseph A. Sorge , Alexey Novoradovsky
发明人： Lars Dyrskjot Andersen , Torben Falck Orntoft , Joseph A. Sorge , Alexey Novoradovsky
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158
摘要： Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis; particularly, determining the expression level of COL4A3BP alone or in combination with expression levels of MBNL2, FABP4, and NEK1 or other markers where increased expression levels of these protective markers relative to a control correlates with lack of bladder cancer progression and decreased expression levels correlate with bladder cancer progression or death. Also disclosed particularly is determining the expression level of COL4A1 alone or in combination with expression levels of UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B or other markers where increased expression levels of these harmful markers relative to a control correlates with bladder cancer progression or death and decreased expression levels correlate with lack of bladder cancer progression. Also disclosed are signatures of protective and harmful markers to predict likelihood of bladder cancer progression or non-progression.
摘要翻译：公开了确定膀胱癌预后的保护性或有害标志物的表达水平; 特别是单独确定COL4A3BP的表达水平或与MBNL2，FABP4和NEK1或其他标志物的表达水平相结合，其中相对于对照组，这些保护性标志物的表达水平增加与膀胱癌进展的缺乏相关，并且降低的表达水平与膀胱癌进展或死亡。还特别公开了确定单独的COL4A1或与UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和CDC25B或其他标志物的表达水平的组合的表达水平，其中这些有害标志物相对于对照相关的这些有害标志物的表达水平与膀胱相关癌症进展或死亡以及降低的表达水平与膀胱癌进展的缺乏相关。还公开了用于预测膀胱癌进展或非进展的可能性的保护性和有害标记物的标志。

9. 发明申请

US20120122722A1 Expression of MBNL2 and Other Genes Associated with Bladder Cancer Progression 审中-公开
标题翻译： MBNL2和其他与膀胱癌进展相关基因的表达
公开(公告)号：US20120122722A1
公开(公告)日：2012-05-17
申请号：US13352435
申请日：2012-01-18
申请人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
IPC分类号： C40B30/04
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.
摘要翻译：公开的是通过确定FABP4和MBNL2或其他标志物的基因表达水平来预测膀胱癌进展的风险的方法，包括膀胱癌的死亡，其中增加的水平与受试者膀胱癌的进展不足相关，并且降低的水平与进展或来自膀胱癌的死亡和/或确定COL4A1，UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和/或CDC25B或其他增加水平与受试者的膀胱癌或死亡进展相关的其他标志物的基因表达水平，并且降低的水平与膀胱癌的进展不良相关。

10. 发明申请

US20120115750A1 Expression of FABP4 and Other Genes Associated with Bladder Cancer Progression 审中-公开
标题翻译： FABP4和其他与膀胱癌进展相关基因的表达
公开(公告)号：US20120115750A1
公开(公告)日：2012-05-10
申请号：US13352393
申请日：2012-01-18
申请人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
发明人： Lars Dyrskjøt Andersen , Torben Falck Orntoft
IPC分类号： C40B30/00 , C12Q1/68
CPC分类号： C12Q1/6876 , C12Q2600/118 , C12Q2600/158
摘要： Disclosed are methods for predicting the risk of bladder cancer progression, including death from bladder cancer by determining gene expression levels of FABP4 and MBNL2 or other markers where increased levels correlate with lack of progression of the subject's bladder cancer, and decreased levels correlate with progression or death from bladder cancer, and/or determining gene expression levels of COL4AI, UBE2C, BIRC5, COLI8A1, KPNA2, MSN, ACTA2, and/or CDC25B or other markers where increased levels correlate with progression of the subject's bladder cancer or death from it, and decreased levels correlate with lack of progression of bladder cancer.
摘要翻译：公开的是通过确定FABP4和MBNL2或其他标志物的基因表达水平来预测膀胱癌进展的风险的方法，包括膀胱癌的死亡，其中增加的水平与受试者的膀胱癌的进展不足相关，并且降低的水平与进展或来自膀胱癌的死亡和/或确定COL4A1，UBE2C，BIRC5，COL18A1，KPNA2，MSN，ACTA2和/或CDC25B或其他标志物的基因表达水平，其中增加的水平与受试者的膀胱癌或死亡的进展相关，并且降低的水平与膀胱癌的进展不良相关。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式